1 Min Read
Sept 6 (Reuters) - RXi Pharmaceuticals Corp:
* RXi Pharmaceuticals announces completion of enrollment of phase 2 clinical trial with samcyprone for cutaneous warts Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.